PF-Atlas › Clinical Trials › NCT03278314

Tezacaftor/Ivacaftor Combination Therapy Expanded Access Program for Patients 12 Years of Age and Older With Cystic Fibrosis

tezacaftor/ivacaftor · Not specified

Registry ID
NCT03278314
Phase
Not specified
Status
Approved For Marketing
Drug / intervention
tezacaftor/ivacaftor
Sponsor
Vertex Pharmaceuticals Incorporated

About this trial

tezacaftor/ivacaftor is evaluated in NCT03278314, a idiopathic pulmonary fibrosis study sponsored by Vertex Pharmaceuticals Incorporated. Current status: Approved For Marketing.

View NCT03278314 on ClinicalTrials.gov →

Explore related

All tezacaftor/ivacaftor trialsAll IPF trials
Medical disclaimer. This page summarizes public trial data for NCT03278314 for information only. It is not medical advice, an endorsement, or an offer to enroll. Confirm details on ClinicalTrials.gov and with a qualified physician.